Sequencing Options of Bispecifics in R/R MM

Focusing on treatment paradigms for patients with relapsed/refractory multiple myeloma, the expert panel discusses the role of BCMA-targeted bispecifics and how they might consider sequencing therapies.

EP: 1.Clinical Scenario 1: A 67-Year-Old Man with Multiple Myeloma

EP: 2.Treatment Options in Late-line R/R MM Patients

Now Viewing

EP: 3.Sequencing Options of Bispecifics in R/R MM

Recent Videos